Inter-atrial shunts are small (5-10 millimeter diameter) permanent devices, placed in the heart via a minimally invasive catheter-based procedure, that connect the left and right atria.

The Corvia Atrial Shunt is the most clinically studied atrial shunt for the reduction of LAP in symptomatic HF patients. It was granted Breakthrough Device designation by the FDA in 2019.

Placement of an atrial shunt device failed to reduce the rate of HF events or improve health status vs. sham in patients with HF with preserved ejection fraction, according to results of the ...

Superior outcomes from the atrial shunt among patients with a peak exercise PVR < 1.74 Wood units vs > 1.74 Wood units in the form of fewer overall heart failure events (0.71 vs 2.48) and greater ...

ATLANTA — Transcatheter implant of an inter-atrial shunt had drastically different results depending on ejection fraction in patients with HF, a speaker reported at the American College of ...

Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, Mass., June 9, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to ...

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. The Lancet , 2022; DOI: 10. ...

Heart failure leaves millions in the U.S. and South Carolina unable to do much and hastens death. MUSC is studying whether a hole in the heart might help them.

Placement of an atrial shunt device intended to reduce pulmonary capillary wedge pressure (PCWP) during exercise in patients with heart failure and preserved ejection fraction (HFpEF) does not reduce ...

While full results from the trial are still pending, early observations point to a prevalence of large shunts among migraine sufferers that is approximately six times that of the general ...

An atrial septal defect (ASD) is an opening between the two upper chambers (atria) of the heart. Learn about the associated symptoms, ... This is known as a left-to-right shunt.

The Corvia Atrial Shunt is the most clinically studied atrial shunt for the reduction of LAP in symptomatic HF patients. It was granted Breakthrough Device designation by the FDA in 2019. The Corvia ...